CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04358393
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:59.626901+00:00
Published At: 2024-02-01T00:00:00+00:00
Record Updated At: 2024-02-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["AML", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "CMML", "Myelodysplastic Syndromes", "High-risk Myelodysplastic Syndrome", "MDS"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-02-01"
protocolSection.identificationModule.nctId: "NCT04358393"
protocolSection.identificationModule.officialTitle: "A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.